SecBot SecBot
SECBOTREPLAY Home › Report › CYTK

CYTK · Cytokinetics presented positive additional Phase 3 results at ESC 2026…

Cytokinetics, Incorporated · PRESS-RELEASE filed Aug 29, 2026 at 10:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Aug 29, 2026 at 10:30 ET

Cytokinetics presented positive additional Phase 3 results at ESC 2026 showing aficamten (MYQORZO) improves cardiac structure and diastolic function in non-obstructive HCM and outperforms metoprolol across pre-trial treatment groups in obstructive HCM. The company plans to submit a supplemental NDA for the nHCM indication in Q4 2026, expanding the drug's potential addressable market beyond the currently approved oHCM population.

  • Additional ACACIA-HCM results showed aficamten significantly improved diastolic function (peak E velocity, septal e' velocity) and reduced left ventricular wall thickness (-0.2 cm, p<0.001) in nHCM at up to 72 weeks.
  • MAPLE-HCM post-hoc analysis showed aficamten improved pVO2 vs metoprolol irrespective of prior beta-blocker use (no beta blockers: +3.1 mL/kg/min, p<0.001; on beta blockers: +1.9 mL/kg/min, p<0.001).
  • Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access